{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:32:13Z","timestamp":1787236333801,"version":"build-2736575974"},"reference-count":30,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Merck Sharp and Dohme UK"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Doravirine is a non-nucleoside reverse transcriptase inhibitor recommended for the treatment of virologically suppressed and treatment na\u00efve people living with HIV. The DRIVE-REAL study aimed to describe the characteristics, treatment patterns, and virological outcomes of doravirine users in a real-world cohort in the UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, observational, multi-centre chart review was conducted for 300 adults living with HIV initiating doravirine-containing antiretroviral therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline 83% of individuals were male, 45% aged \u226550\u00a0years, 65% white ethnicity. Median time since HIV diagnosis was 12\u00a0years. 96% were antiretroviral therapy-experienced, 87% had a HIV viral load &lt;50 copies\/ml, and 15% had resistance to at least one antiretroviral drug. 66% had comorbidities, most commonly depression (26%), and 70% were taking at least one co-medication. At six months, 94% ( n = 283\/300) were still receiving doravirine. Viral load data were available for n = 266\/300 individuals and 95% ( n = 253\/266) had viral load &lt;50\u00a0copies\/ml.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Individuals initiating doravirine in this cohort are predominantly treatment-experienced white middle-aged males, with a high frequency of comorbidities and co-medication. The majority of individuals at 6 months remained on doravirine and maintained or achieved HIV viral suppression. This study provides epidemiologic characteristics that can inform clinical care and subsequent hypothesis-testing studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09564624231215977","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T08:11:06Z","timestamp":1700122266000},"page":"206-216","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Real world utilisation of doravirine among people living with human immunodeficiency virus in England (DRIVE-REAL)"],"prefix":"10.1177","volume":"35","author":[{"given":"Charlotte","family":"O\u2019Halloran","sequence":"first","affiliation":[{"name":"Medical Affairs (HIV), MSD (UK) Limited, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Gilleece","sequence":"additional","affiliation":[{"name":"HIV and Sexual Health, Brighton & Sussex Medical School and University Hospitals Sussex NHS Trust, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suki","family":"Leung","sequence":"additional","affiliation":[{"name":"St Stephen\u2019s Centre, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Canuto","sequence":"additional","affiliation":[{"name":"St Stephen\u2019s Centre, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"McAlpine","sequence":"additional","affiliation":[{"name":"College London and Mortimer Market Centre, Centre for Clinical Research in Infection and Sexual Health University, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0482-669X","authenticated-orcid":false,"given":"Sophie","family":"Ross","sequence":"additional","affiliation":[{"name":"HIV and Sexual Health, Brighton & Sussex Medical School and University Hospitals Sussex NHS Trust, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Norcross","sequence":"additional","affiliation":[{"name":"HIV and Sexual Health, Brighton & Sussex Medical School and University Hospitals Sussex NHS Trust, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Gaffney","sequence":"additional","affiliation":[{"name":"Medical Affairs (HIV), MSD (UK) Limited, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nipur","family":"Siani","sequence":"additional","affiliation":[{"name":"Medical Affairs (HIV), MSD (UK) Limited, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9718-1280","authenticated-orcid":false,"given":"William","family":"Hickey","sequence":"additional","affiliation":[{"name":"Medical Affairs (HIV), MSD (UK) Limited, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Moore","sequence":"additional","affiliation":[{"name":"Adelphi Real World (ARW), Bollington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivera","family":"Rajkovic-Hooley","sequence":"additional","affiliation":[{"name":"Adelphi Real World (ARW), Bollington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Milinkovic","sequence":"additional","affiliation":[{"name":"St Stephen\u2019s Centre, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK"},{"name":"Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"bibr1-09564624231215977","volume-title":"HIV testing, new HIV diagnoses, outcomes and quality of care for people accessing HIV services: 2021 report. The annual official statistics data release (data to end of December 2020)","author":"Martin V","year":"2021"},{"key":"bibr2-09564624231215977","volume-title":"DRIVE-FORWARD and DRIVE-AHEAD 192-week","author":"Molina JM","year":"2021"},{"key":"bibr3-09564624231215977","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02650-15"},{"key":"bibr4-09564624231215977","volume-title":"[Online] Pifeltro (doravirine)","author":"European Medicines Agency","year":"2022"},{"key":"bibr5-09564624231215977","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy540"},{"key":"bibr6-09564624231215977","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30021-3"},{"key":"bibr7-09564624231215977","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000471"},{"key":"bibr8-09564624231215977","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0512-5"},{"key":"bibr9-09564624231215977","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002642"},{"key":"bibr10-09564624231215977","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002725"},{"key":"bibr11-09564624231215977","volume-title":"EACS Guidelines version 11.0","author":"(EACS). European AIDS Clinical Society","year":"2021"},{"key":"bibr12-09564624231215977","volume-title":"BHIVA guidelines on antiretroviral treatment for adults living with HIV-1","author":"BHIVA","year":"2022"},{"key":"bibr13-09564624231215977","volume-title":"Genotypic resistance interpretation algorithm 9.0 (version 3.2.1update 2021-03-21)","author":"Stanford U"},{"key":"bibr14-09564624231215977","volume-title":"Understand cholesterol and triglyceride results","author":"HEART UK","year":"2021"},{"key":"bibr15-09564624231215977","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/heartjnl-2014-305650","volume":"100","author":"JBS3 Board","year":"2014","journal-title":"Heart"},{"key":"bibr16-09564624231215977","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002056"},{"key":"bibr17-09564624231215977","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-008-0010-6"},{"key":"bibr18-09564624231215977","volume-title":"Positive voices: the national survey of people living with HIV - findings from the 2017 survey","author":"Kall M","year":"2020"},{"key":"bibr19-09564624231215977","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv183"},{"key":"bibr20-09564624231215977","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0293"},{"key":"bibr21-09564624231215977","volume-title":"SmPC for SUSTIVA\u00ae600mg film-coated tablets (efavirenz). emc. [Online]","author":"Electronic Medicines Compendium (emc)","year":"2021"},{"key":"bibr22-09564624231215977","unstructured":"Etravirine SmPC. The electronic medicines compendium (emc). Etravirine SmPC, 2021. [Online] https:\/\/www.medicines.org.uk\/emc\/product\/7636\/smpc#gref."},{"key":"bibr23-09564624231215977","volume-title":"Prescribing information for EDURANT\u00ae(rilpivirine)","author":"Janssen-Cilag Ltd","year":"2022"},{"key":"bibr24-09564624231215977","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.863708"},{"key":"bibr25-09564624231215977","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835f1db0"},{"key":"bibr26-09564624231215977","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu234"},{"key":"bibr27-09564624231215977","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.16.1.18567"},{"key":"bibr28-09564624231215977","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002730"},{"key":"bibr29-09564624231215977","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029855"},{"key":"bibr30-09564624231215977","volume-title":"BHIVA Guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals","author":"BHIVA","year":"2019"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624231215977","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09564624231215977","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09564624231215977","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:45:12Z","timestamp":1777675512000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09564624231215977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1177\/09564624231215977"],"URL":"https:\/\/doi.org\/10.1177\/09564624231215977","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]}}}